70860-225 NDC - BORTEZOMIB ()

Drug Information

Product NDC: 70860-225

Proprietary Name: Bortezomib

Non Proprietary Name:

Active Ingredient(s):

Administration Route(s):

Dosage Form(s):

Labeler Name:	Athenex Pharmaceutical Division, LLC.
Product Type:
FDA Application Number:
Marketing Category:
Start Marketing Date:	5/6/2022

No.	Package Code	Package Description	Billing Unit
1	70860-225-10	1 VIAL, SINGLE-DOSE in 1 CARTON (70860-225-10) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE	EA

Field Name	Field Value	Definition
PRODUCT NDC	70860-225	The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PROPRIETARY NAME	Bortezomib	The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
START MARKETING DATE	5/6/2022	This is the date that the labeler indicates was the start of its marketing of the drug product.
LABELER NAME	Athenex Pharmaceutical Division, LLC.	Name of Company corresponding to the labeler code segment of the Product NDC.

Export to text format icon Download this NDC record in Text format: Export

Export to text format icon Download this NDC record in Excel (CSV) format: Export

Export to text format icon Download this NDC record in XML format: Export

This page was last updated on: 5/3/2024